Minerva Neurosciences to Report Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates on March 13, 2017
March 06, 2017 08:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia
February 21, 2017 08:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer
December 20, 2016 08:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting
December 05, 2016 08:00 ET
|
Minerva Neurosciences, Inc.
Oral presentation highlights specific improvements in negative symptoms and cognition observed in schizophrenic patients treated with MIN-101 in Phase IIB trial Data also presented from Phase IIA...
Minerva Neurosciences Reports Third Quarter 2016 Financial Results and Business Updates
November 03, 2016 07:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia
October 26, 2016 08:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting
October 13, 2016 08:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs
September 26, 2016 08:30 ET
|
Minerva Neurosciences, Inc.
Last patient completes extension phase of Phase IIb trial with MIN-101 Company receives FDA acceptance of Investigational New Drug Application for MIN-117 WALTHAM, Mass., Sept. 26, 2016 (GLOBE...
Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates
August 04, 2016 07:30 ET
|
Minerva Neurosciences, Inc.
Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder Additional trials also planned with MIN-202 in insomnia disorder and major...
Minerva Neurosciences Announces Positive Results From Phase IIB Trial of MIN-101 Monotherapy in Schizophrenia
May 26, 2016 08:00 ET
|
Minerva Neurosciences, Inc
Statistically significant improvement in PANSS negative symptoms and total PANSS scores observed MIN-101 shown to be statistically superior on key secondary endpoints Effect of MIN-101...